Form 4: Capricor CEO Marban Receives Significant Equity Grant

Capricor Therapeutics CEO Linda Marban was granted 150,000 stock options and 7,500 restricted stock units on January 5, 2026, as part of her annual equity compensation.

Summary

• Linda Marban, Chief Executive Officer and Director of Capricor Therapeutics, Inc. (CAPR), reported an acquisition of derivative securities.
• On January 5, 2026, Marban was granted 150,000 stock options and 7,500 restricted stock units (RSUs).
• One stock option grant for 50,000 shares has an exercise price of $24.81 and vests 1/48th monthly, commencing February 1, 2026, with an expiration date of January 5, 2036.
• A second stock option grant for 100,000 shares also has an exercise price of $24.81 and vests upon U.S. Food and Drug Administration (FDA) approval of Deramiocel, with an expiration date of January 5, 2027.
• The 7,500 restricted stock units were granted as part of the Issuer's annual equity grant to executive officers and vest annually at a rate of 25% commencing February 1, 2027.
• All grants are subject to Marban's continued service to the Issuer through their respective vesting dates.

Sentiment

Score: 7

Explanation: The equity grants to the CEO are generally positive as they align management incentives with shareholder value and key company milestones. However, the reliance on FDA approval for a significant portion of the options, coupled with a relatively short expiration window, introduces a degree of uncertainty and pressure.

Positives

• The significant equity grants to the CEO align her interests directly with long-term shareholder value and the company's strategic objectives.
• Tying the vesting of 100,000 stock options to FDA approval of Deramiocel signals management's confidence in the drug's potential and provides a strong incentive for achieving this critical regulatory milestone.

Negatives

• The short expiration date of January 5, 2027, for the 100,000 stock options tied to FDA approval of Deramiocel implies a tight timeline for this critical milestone, potentially adding pressure or indicating a near-term expectation that might not materialize.

Risks

• The vesting of 100,000 stock options is contingent on FDA approval of Deramiocel by January 5, 2027, introducing significant regulatory and timeline risk.
• If the reporting person elects to early exercise the 50,000 stock options and her service terminates prior to vesting, the shares will be subject to a repurchase option in favor of the Issuer.

Future Outlook

The vesting conditions for a significant portion of the CEO's equity grant are tied to the future FDA approval of Deramiocel, indicating a key upcoming milestone for the company. The short expiration date for these options suggests an expectation of this approval within the next year.

Management Comments

• The restricted stock units were granted on January 5, 2026, as part of the Issuer's annual equity grant to executive officers.

Industry Context

Equity grants are a standard component of executive compensation in the biotechnology and pharmaceutical industries, often structured to align management incentives with critical development milestones, such as regulatory approvals, which are key value drivers in this sector.

Comparison to Industry Standards

• The filing does not provide specific comparable company data or project results to assess the equity grants against global benchmarks.
• Tying executive equity compensation to key regulatory milestones, such as FDA approval, is a common practice in the biotechnology industry to align management incentives with critical value-driving events.

Corporate Governance

Related Party Transactions

• The equity grants to Linda Marban, the Chief Executive Officer and a Director, constitute a related party transaction, which is disclosed as part of her compensation.

Stakeholder Impact

• Shareholders: The equity grants are designed to align the CEO's financial interests with the long-term performance of the company and the successful development of its pipeline, potentially benefiting shareholders through increased motivation for value creation.
• Employees: The grants represent a standard form of executive compensation, which may influence compensation structures for other key personnel.

Next Steps

• Continued service by Linda Marban to ensure vesting of the equity grants.
• Progress towards U.S. Food and Drug Administration (FDA) approval of Deramiocel, which is a condition for the vesting of 100,000 stock options.

Key Dates

Keywords

Capricor Therapeutics, CAPR, Linda Marban, SEC Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Equity Grant, CEO Compensation, Deramiocel, FDA Approval